Oppenheimer Maintains Outperform on Denali Therapeutics, Lowers Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $70 to $68.
June 06, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Denali Therapeutics (DNLI) but lowers the price target from $70 to $68.
The news of Oppenheimer maintaining an Outperform rating on Denali Therapeutics (DNLI) is positive for the company. However, the lowering of the price target from $70 to $68 may have a neutral impact on the stock price in the short term, as it indicates a slight decrease in the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100